Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular breast imaging

This article was originally published in The Gray Sheet

Executive Summary

Procedure may be a useful adjunct to mammography screens in detecting breast cancer in women at risk for the disease or with dense breasts, according to a study presented at the American Society of Clinical Oncology's annual Breast Cancer Symposium Sept. 5-7 in Washington, D.C. A 15-month follow-up of 375 women in the 940-patient trial, conducted at the Mayo Clinic in Rochester, Minn., showed that MBI had 75% sensitivity and 93.2% specificity, compared to 25% sensitivity and 91.3% specificity with mammography. The next step is to compare the technology to magnetic resonance imaging and other screening methods, lead investigator Carrie Hruska noted in a Sept. 3 press release. MBI costs more than mammography, but one-fifth less than MRI, according to the study authors
Advertisement

Related Content

Research In Brief
Advertisement
UsernamePublicRestriction

Register

MT026545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel